Companies / Pdl Biopharma, Inc.
Pdl Biopharma, Inc.
PDLICIK 882104
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Dec 30, 2020 | Silver Point Capital L.P. 10% owner | Buy Open-market buy | Common Stock | $15.81M | +6.3M +36.23% | 23,783,273 | high |
| Jan 28, 2015 | McLaughlin John Peter CEO | Grant Grant or award | Common stock | $984.5K | +129K +44.79% | 417,669 | low |
| Feb 1, 2021 | Silver Point Capital L.P. 10% owner | Buy Open-market buy | Common Stock | $383.5K | +187K +0.79% | 23,970,334 | medium |
| Jan 28, 2015 | Stone Christopher Lewis Executive | Grant Grant or award | Common stock | $252.3K | +33K +30.84% | 140,473 | low |
| Jan 28, 2015 | Garcia Peter S Executive | Grant Grant or award | Common stock | $250.3K | +33K +76.34% | 75,872 | low |
| Jan 28, 2015 | Hart Danny J Jr. Executive | Grant Grant or award | Common stock | $217.5K | +29K +57.81% | 77,920 | low |
| Jan 28, 2015 | Montez David Executive | Grant Grant or award | Common stock | $91.1K | +12K +81.05% | 26,719 | low |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| PDLI | common | 69329Y104 |